We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
If you are a frequent customer of commercial laboratory testing services in North America, you probably have been offered one or more diagnostic products of one of its leading providers– Quest Diagnostics Inc. (DGX - Free Report) . Apart from the U.S., this company provides its laboratory services in several international markets including parts of India, England, Mexico and Puerto Rico.
Currently, Quest Diagnostics has a Zacks Rank #3 (Hold) but that could change following its strong second quarter 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings:The Zacks Consensus Estimate remained steady at $1.31 per share over the last 30 days. Quest Diagnostics’ adjusted earnings per share of $1.34 beat this estimate by 2.3%.
Revenues:Quest Diagnostics posted revenues of $1.91 billion, beating the Zacks Consensus Estimate for revenues of $1.90 billion.
Key Stats: Quest Diagnostics’ volume, measured by the number of requisitions, increased 1.9% versus the prior year’s volume and revenue per requisition rose by 0.2%. Diagnostic Information Services revenues grew 2.2% year over year.
Major Factors: Quest Diagnostics delivered strong results in the second quarter. According to management, the company’s expanding relationships with hospitals, including the CLP acquisition and Barnabas Health PLS agreement, have been key contributors to this growth. Going forward, management expects Quest Diagnostic’ latest PLS agreement with HCA's HealthONE system to help the company in continuing this momentum. The company also noticed substantial improvements in its cost savings initiatives as well as customer experience this quarter.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Quest Diagnostics earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Quest Diagnostics (DGX) Tops Q2 Earnings & Revenue Estimates
If you are a frequent customer of commercial laboratory testing services in North America, you probably have been offered one or more diagnostic products of one of its leading providers– Quest Diagnostics Inc. (DGX - Free Report) . Apart from the U.S., this company provides its laboratory services in several international markets including parts of India, England, Mexico and Puerto Rico.
Currently, Quest Diagnostics has a Zacks Rank #3 (Hold) but that could change following its strong second quarter 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings:The Zacks Consensus Estimate remained steady at $1.31 per share over the last 30 days. Quest Diagnostics’ adjusted earnings per share of $1.34 beat this estimate by 2.3%.
Revenues:Quest Diagnostics posted revenues of $1.91 billion, beating the Zacks Consensus Estimate for revenues of $1.90 billion.
QUEST DIAGNOSTC Price and EPS Surprise
QUEST DIAGNOSTC Price and EPS Surprise | QUEST DIAGNOSTC Quote
Key Stats: Quest Diagnostics’ volume, measured by the number of requisitions, increased 1.9% versus the prior year’s volume and revenue per requisition rose by 0.2%. Diagnostic Information Services revenues grew 2.2% year over year.
Major Factors: Quest Diagnostics delivered strong results in the second quarter. According to management, the company’s expanding relationships with hospitals, including the CLP acquisition and Barnabas Health PLS agreement, have been key contributors to this growth. Going forward, management expects Quest Diagnostic’ latest PLS agreement with HCA's HealthONE system to help the company in continuing this momentum. The company also noticed substantial improvements in its cost savings initiatives as well as customer experience this quarter.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Quest Diagnostics earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>